Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript
11:52pm, Thursday, 25'th Apr 2024
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Jane Hanlon - Associate Director of Investor Relations Matthew Klein - Chief Execu
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
09:01pm, Thursday, 25'th Apr 2024
Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wal
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
04:05pm, Thursday, 25'th Apr 2024
– Strong revenue performance across product portfolio – – Submitted MAA for sepiapterin and BLA for Upstaza – – On target to achieve remaining 2024 clinical and regulatory milestones, incl
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 23'rd Apr 2024
WARREN, N.J. , April 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 19, 2024, the company approved non-statutory stock options to purchase an aggregate of
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Thursday, 18'th Apr 2024
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
08:00am, Thursday, 11'th Apr 2024
SOUTH PLAINFIELD, N.J., April 11, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 finan
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
08:30am, Thursday, 28'th Mar 2024
- First marketing authorization submission for sepiapterin with additional global submissions to follow in 2024 - SOUTH PLAINFIELD, N.J. , March 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDA
PTC Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PTCT
07:20am, Tuesday, 26'th Mar 2024
NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o
PTC Therapeutics, Inc. (PTCT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
07:30am, Monday, 25'th Mar 2024
NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o
PTCT ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your PTC Therapeutics, Inc. investment
07:20am, Friday, 22'nd Mar 2024
NEW YORK, NY / ACCESSWIRE / March 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o
NEW YORK, NY / ACCESSWIRE / March 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
03:01pm, Wednesday, 20'th Mar 2024
PTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to resubmit its application for Translarna to the regulatory body. Its shares rise on these updates.
PTC Therapeutics Provides Key Regulatory Updates
07:30am, Tuesday, 19'th Mar 2024
- BLA submitted to FDA for Upstaza™ for the treatment of AADC deficiency - - NDA to be submitted mid-year for Translarna™ based on FDA feedback - SOUTH PLAINFIELD, N.J., March 19, 2024 /PRNewsw
NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o
PTC Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by PTC (PTCT)
07:25am, Wednesday, 13'th Mar 2024
NEW YORK, NY / ACCESSWIRE / March 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o
